Thalidomide in cutaneous lupus erythematosus

Cutaneous Lupus Erythematosus

Volumn , Issue , 2005, Pages 391-401

  Karim, Yousuf ^a   Cuadrado, Maria J ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33645454971     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/3-540-26581-3_28     Document Type: Chapter

References (58)

1. Aronson IK, Yu R, West DP, van den Broek H, Antel J (1984) Thalidomide induced peripheral neuropathy. Arch Dermatol 120:1466-1470
2. Atra E, Sato EI (1993) Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol 11:487-493
3. Barnhill RL, Doll NJ, Millikan LE, Hastings RC (1984) Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes. J Am Acad Dermatol 11:814-819
4. Belmont HM, Buyon J, Giorno R, Abramson S (1994) Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus. The Shwartzman phenomenon revisited. Arthritis Rheum 37:376-383
5. Clemmensen OJ, Olsen PZ, Andersen KE (1984) Thalidomide neurotoxicity. Arch Dermatol 120:338-341
6. Corral LG, Kaplan G (1999) Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis 58(Suppl I):I107-113
7. D'Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082-4085
8. de Iongh RU (1990) A quantitative ultrastructural study of motor and sensory lumbosacral nerve roots in the thalidomide-treated rabbit fetus. J Neuropathol Exp Neurol 49:564-581
9. Dean GS, Tyrell-Price J, Crawley E, Isenberg DA (2000) Cytokines and systemic lupus erythematosus. Ann Rheum Dis 59:243-251
10. Duong DJ, Spigel GT, Moxley TR 3rd, Gaspari AA (1999) American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus. Arch Dermatol 135:1079-1087
11. Faure M, Thivolet J, Gaucherand M (1980) Inhibition of PMN leukocytes chemotaxis by thalidomide. Arch Dermatol Res 269:275-280
12. Flageul B, Wallach D, Cavalier-Balloy B, Bachelez H, Carsuzaa F, Dubertret L (2000) Thalidomide and thrombosis. Ann Dermatol Venereol 127:171-174
13. Frances C, El Khoury S, Gompler A, Becherel PA, Chosidow O, Piette JC (2002) Transient secondary amenorrhea in women treated by thalidomide. Eur J Dermatol 12:63-65
14. Fullerton PM, O'Sullivan DJ (1968) Thalidomide neuropathy: a clinical, electrophysiological, and histological follow-up study. J Neurol Neurosurg Psychiatric 31:543-551
15. Gad SM, Shannon EJ, Krotoski WA, Hastings RC (1985) Thalidomide induces imbalances in T-lymphocyte sub-populations in the circulating blood of healthy males. Lepr Rev 56:35-39
16. Gardner-Medwin JM, Smith NJ, Powell RJ (1994) Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 53:828-832
17. Geitz H, Handt S, Zwingenberger K (1996) Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 31:213-221
18. Gompel A, Frances C, Piette JC, Blanc AS, Cordoliani F, Piette AM (1999) Ovarian failure with thalidomide treatment in complex aphthosis: comment on the concise communication by Ordi et al. Arthritis Rheum 42:2259-2260
19. Gutierrez-Rodriguez O, Starusta-Bacal P, Gutierrez-Montes O (1989) Treatment of rheumatoid arthritis: the thalidomide experience. J Rheumatol 16:158-163
20. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, Zwingenberger K, Yazici H (1998) Thalidomide in the treatment of the mucocutaneous lesions of Behcet's syndrome. A randomised, double-blind, placebo controlled trial. Ann Intern Med 128:443-459
21. + subset. J Exp Med 187:1885-1892
22. Herrera-Esparza R, Barbosa-Cisneros O, Villalobos-Hurtando R, Avalos-Diaz E (1998) Renal expression of IL-6 and TNF alpha genes in lupus nephritis. Lupus 7:154-158
23. Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen JA, McDevitt HO (1990) Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA 87:1233-1237
24. Jones SM, Mathew CM, Dixey J, Lovell CR, McHugh NJ (1996) VCAM-1 expression on endothelium in lesions from cutaneous lupus erythematosus is increased compared with systemic and localized scleroderma. Br J Dermatol 135:678-686
25. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr (2001) Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 276:22382-22387
26. Knop J, Bonsmann G, Happle R, Ludolph A, Matz DR, Mifsud EJ, Macher E (1983) Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol 108:461-466
27. Kohchiyama A, Oka D, Ueki H (1985) T-cell subsets in lesions of systemic and discoid lupus erythematosus. J Cutan Pathol 12:493-499
28. Kruse FE, Joussen AM, Rohrschneider K, Becker MD, Volcker HE (1998) Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 236:461-466
29. Kyriakis KP, Kontochristopoulos GJ, Panteleos DN (2000) Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus. Int J Dermatol 39:218-222
30. Lagueny A, Rommel A, Vignolly B, Taieb A, Vendeaud-Busquet M, Doutre MS, Julien J (1986) Thalidomide neuropathy: an electrophysiologic study. Muscle Nerve 9:837-844
31. *2 homozygote: an important predisposing factor of lupus nephritis in Koreans. Lupus 6:603-609
32. McHugh SM, Rifkin IR, Deighton J Wilson AB, Lachmann PJ, Lockwood CM, Ewan PW (1995) The immunosuppressive drug thalidomide induces T helper type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen-and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 99:160-167
33. Mellin GW, Katzenstein M (1962) The saga of thalidomide: neuropathy to embryopathy, with case reports and congenital abnormalities. N Engl J Med 23:1184-1190
34. Mellin GW (1962) The saga of thalidomide (concluded). N Engl J Med. 267:1238-1244
35. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor a production by enhancing mRNA degradation. J Exp Med 177:1675-1680
36. Moreira AL, Friedlander DR, Shif B, Kaplan G, Zagzag D (1999) Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro. J Neurooncol 43:109-114
37. Ochonisky S, Verroust J, Bastuji-Garin S, Gherardi R, Revuz J (1994) Thalidomide neuropathy incidence and clinicoelectrophysiologic findings in 42 patients. Arch Dermatol 130:66-69
38. Ordi-Ros J, Cortes F, Martinez N, Mauri M, de Torres I, Vilardell M (1998) Thalidomide induces amenorrhea in patients with lupus disease. Arthritis Rheum 41:2273-2275
39. Ordi-Ros J, Cortes F, Cucurull E, Mauri M, Bujan S, Vilardell M (2000) Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy. J Rheumatol 27:1429-1433
40. Osman K, Comenzo R, Rajkumar SV (2001) Deep vein thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 344:1951-1952
41. Passeron T, Lacour JP, Murr D, Ortonne JP (2001) Thalidomide-induced amenorrhea: two cases. Br J Dermatol 144:1262-1295
42. Powell RJ, Gardner-Medwin JM (1994) Guideline for the clinical use and dispensing of thalidomide. Postgrad Med J 70:901-904
43. Randall T (1990) Thalidomide has 37-year history. JAMA 263:1474
44. Rao DG, Kane NM, Oware A (2000) Thalidomide neuropathy: role of F-wave monitoring. Muscle Nerve 23:1301-1302
45. Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V, Arroyo-Figueroa H, Pasquetti A, Calva JJ, Ruiz-Palacios GM (1996) Effects of thalidomide on HIV-associated wasting syndrome: a randomised, double-blind, placebo-controlled clinical trial. AIDS 10:1501-1507
46. Rovelli A, Amigo C, Nesi F, Balduzzi A, Nicolini B, Locasciulli A, Vassallo E, Miniero R, Uderzo C (1998) The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation. Bone Marrow Transplant 21:577-581
47. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G (1991) Thalidomide selectively inhibits tumor necrosis factor a production by stimulated human monocytes. J Exp Med 173:699-703
48. Sato EI, Assis LS, Lorenzi VP, Andrade LE (1998) Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus. Rev Assoc Med Bras 44:289-293
49. Settles B, Stevenson A, Wilson K, Mack C, Ezell T, Davis MF, Taylor LD (2001) Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide. Cell Mol Biol (Noisy-le-grand) 47:1105-1114
50. Shannon EJ, Miranda RO, Morales MJ, Hastings RC (1981) Inhibition of de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy. Scand J Immunol 13:553-562
51. Sheskin J (1965) Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 6:303-306
52. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B 1999 Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571
53. Stevens RJ, Andujar C, Edwards CJ, Ames P R J, Barwick AR, Khamashta MA, Hughes G R V (1997) Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. Br J Rheumatol 36:353-359
54. Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL (1996) Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 35:969-979
55. Vogelsang GB (1993) Acute and chronic graft-versus-host disease. Curr Opin Oncol 5:276-281
56. Walchner M, Messer G, Wierenga EA (1995) Reconstitution of transcription factor binding to the conserved lymphokine element-o and downregulation of NF-kB activity after thalidomide treatment of systemic lupus erythematosus. Arch Dermatol Res 287:347
57. Walchner M, Meurer M, Plewig G, Messer G (2000) Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus. Int J Dermatol 39:383-388
58. Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, Maignan M, Schuhmacher MH, Milpied B, Pilorget A, Bocquet H, Brun-Buisson C, Revuz J 1998 Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 352:1586-1589